The United Kingdom's FTSE 100 index has recently experienced declines, influenced by weak trade data from China and falling commodity prices. In such a fluctuating market, identifying undervalued stocks can be crucial for investors looking to capitalize on potential growth opportunities.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Click here to see the full list of 58 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Redcentric

Overview: Redcentric plc, with a market cap of ￡217.39 million, provides IT managed services for both public and private sectors in the United Kingdom.

Operations: The company generates ￡163.15 million from providing managed services to customers in the United Kingdom.

Estimated Discount To Fair Value: 44.6%

Redcentric, trading at ￡1.37, is significantly undervalued compared to its estimated fair value of ￡2.48. The company's earnings have grown 1.9% annually over the past five years and are forecast to grow 63.79% per year, with revenue expected to increase by 4.9% annually, outpacing the UK market's growth rate of 3.7%. Despite reporting a net loss of ￡3.44 million for the year ended March 31, 2024, Redcentric's financial outlook remains positive as it is expected to become profitable within three years and achieve a high return on equity (23.8%).

• Upon reviewing our latest growth report, Redcentric's projected financial performance appears quite optimistic.

• Get an in-depth perspective on Redcentric's balance sheet by reading our health report here.

AstraZeneca

Overview: AstraZeneca PLC is a biopharmaceutical company that focuses on the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of ￡204.64 billion.

Operations: AstraZeneca generates $49.13 billion in revenue from its biopharmaceuticals segment.

Estimated Discount To Fair Value: 46.9%

AstraZeneca, trading at ￡132, is significantly undervalued with an estimated fair value of ￡248.62. Despite a high level of debt, the company has demonstrated strong earnings growth of 4.5% over the past year and is forecasted to grow by 16.6% annually, outpacing the UK market's growth rate. Recent FDA approval for Imfinzi in treating early-stage NSCLC enhances its revenue prospects further solidifying its financial position amidst ongoing legal challenges related to patent infringement cases.

• Our comprehensive growth report raises the possibility that AstraZeneca is poised for substantial financial growth.

• Click here to discover the nuances of AstraZeneca with our detailed financial health report.

Gym Group

Overview: The Gym Group plc, with a market cap of ￡256.26 million, operates a network of gym facilities under the Gym Group brand name in the United Kingdom.

Operations: The company's revenue primarily comes from the provision of high-quality health and fitness facilities, amounting to ￡204 million.

Estimated Discount To Fair Value: 10.7%

Gym Group, trading at ￡1.43, is undervalued by 10.7% against its estimated fair value of ￡1.61. While the revenue growth forecast of 8.5% per year outpaces the UK market's 3.7%, it remains below a high-growth threshold and profitability is expected within three years with earnings projected to grow significantly annually at over 100%. However, return on equity is forecast to be low at 1.5%, reflecting potential challenges in generating shareholder returns despite positive cash flow indicators.

• In light of our recent growth report, it seems possible that Gym Group's financial performance will exceed current levels.

• Click here and access our complete balance sheet health report to understand the dynamics of Gym Group.

Seize The Opportunity

• Click through to start exploring the rest of the 55 Undervalued UK Stocks Based On Cash Flows now.

• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.

• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:RCN LSE:AZN and LSE:GYM.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]